Abstract:BACKGROUND:In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alterations occurring in these tumors could explain the prognostic heterogeneity observed in these patients.METHODS:We retrospectively analyzed 96 patients with NSCLC with ALK detected by immunohistochemical staining (VENTANA anti-ALK(D5F3) Rabbit Monoclonal Primary Antibody). Cancer tissues were subjected to next-generation sequencing using a panel of 520 cancer-related genes. The genomic landscape, distribution of ALK fusion variants, and clinicopathological characteristics of the patients were evaluated. The correlations of genomic alterations with clinical outcomes were also assessed.RESULTS:Among the 96 patients with immunohistochemically identified ALK fusions, 80 (83%) were confirmed by next-generation sequencing. TP53 mutation was the most commonly co-occurring mutation with ALK rearrangement. Concomitant driver mutations [2 Kirsten rat sarcoma viral oncogene homolog (KRAS) G12, 1 epidermal growth factor receptor (EGFR) 19del, and 1 MET exon 14 skipping] were also observed in 4 adenocarcinomas. Echinoderm microtubule associated protein-like 4 (EML4)-ALK fusions were identified in 95% of ALK-rearranged patients, with 16.2% of them also harboring additional non-EML4-ALK fusions. Nineteen non-EML4 translocation partners were also discovered, including 10 novel ones. Survival analyses revealed that patients concurrently harboring PIK3R2 alterations showed a trend toward shorter progression-free survival (6 vs. 13 months, P=0.064) and significantly shorter overall survival (11 vs. 32 months, P=0.004) than did PIK3R2-wild-type patients. Patients with concomitant alterations in PI3K the signaling pathway also had a shorter median overall survival than those without such alterations (23 vs. 32 months, P=0.014), whereas progression-free survival did not differ significantly.CONCLUSIONS:The spectrum of ALK-fusion variants and the landscape of concomitant genomic alterations were delineated in 96 NSCLC patients. Our study also demonstrated the prognostic value of concomitant alterations in crizotinib-treated patients, which could facilitate improved stratification of ALK-rearranged NSCLC patients in the selection of candidates who could optimally benefit from therapy.

Supplementary Figure 1 from the Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

Supplementary Figure 4 from the Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of <i>alk</i> Transcripts to Detect <i>alk</i> Rearrangements in Lung Cancers

Supplementary Figure 2 from the Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of <i>alk</i> Transcripts to Detect <i>alk</i> Rearrangements in Lung Cancers

Supplementary Table 1 from the Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of <i>alk</i> Transcripts to Detect <i>alk</i> Rearrangements in Lung Cancers

The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers

Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figure 1 from Lung Cancers with Concomitant <i>egfr</i> Mutations and <i>alk</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Screening of Nsclc Samples from Chinese Lung Cancer Patients for Activating Rearrangements of the Alk, Ret, and Ros1 Genes.

Supplementary Figure 2 from Lung Cancers with Concomitant <i>egfr</i> Mutations and <i>alk</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Supplementary Figure 4 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.

A Novel Homebrew Real-Time PCR Assay to Detect ALK Rearrangements in Lung Cancers and Lymphomas.

Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Supplementary Figure 2 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

Diagnostic Value Of A Novel Real-Time Reverse Transcription-Polymerase Chain Reaction For Detection Of Alk Rearrangement In Lung Adenocarcinoma

Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Figure 5 from Identification of Anaplastic Lymphoma Kinase As a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer